Fortress Biotech, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Fortress Biotech, Inc. Fortress Biotech, Inc. (Nasdaq: FBIO) is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative pharmaceutical and biotechnology products across oncology, dermatology, rare diseases, and gene therapy; the company markets eight prescription products including Emrosi (minocycline hydrochloride extended-release capsules) for rosacea, Qbrexza (medicated cloth towelette) for primary axillary hyperhidrosis, Accutane (oral isotretinoin) for severe acne, Amzeeq (topical minocycline) for acne vulgaris, Zilxi for rosacea, and additional dermatology offerings through subsidiary Journey Medical Corporation, alongside development programs such as CUTX-101 (copper histidine injection) for Menkes disease and cosibelimab (UNLOXCYT) for advanced cutaneous squamous cell carcinoma. Founded in 2006 and headquartered in Bay Harbor Islands, Florida, Fortress operates through a network of majority-owned subsidiaries and partners including AstraZeneca, City of Hope, and Sentynl, with geographic focus on the United States and global clinical development activities. Recent developments include FDA approvals in late 2024 for Emrosi and UNLOXCYT, the 2025 commercial launch of Emrosi generating initial prescriptions and expanded payer coverage to 65% of commercial lives, the sale of subsidiary Checkpoint Therapeutics to Sun Pharma yielding approximately $28 million plus a 2.5% royalty on UNLOXCYT net sales and potential contingent value right payments up to $4.8 million, a strategic AI-driven collaboration with Partex NV in March 2025 for biopharmaceutical compound evaluation, and subsidiary Urica Therapeutics securing a $205 million Series A financing for Crystalys Therapeutics advancing dotinurad Phase 3 trials for gout with Fortress retaining equity and a 3% royalty.
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average – Here’s What Happened
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving Average – What’s Next?
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States